M

    MacroGenics Inc (MGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.99
    -0.14 (-3.39%)

    Market Cap: $263.08M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -18.71%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.68 - $-0.05
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.31-15.7%
    60d ago$-0.31-15.7%
    30d ago$-0.31-15.7%
    7d ago$-0.31-15.7%
    Current$-0.27
    Revenue Consensus
    $41M
    Range$10M - $62M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.18
    Range$-0.18 - $-0.18
    1 analysts
    Revenue Consensus
    $-402010
    Range$-49580840 - $33M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.18---
    Sep 26EST
    		-$-0.27---
    Jun 26
    		$-0.27$-0.34+20.59%Beat+52.6%
    Mar 26
    		$-0.58$-0.55-5.45%Miss+10.8%
    Dec 25
    		$-0.22$-0.27+18.40%Beat+73.1%
    Sep 25
    		$0.27$-0.44+161.36%Beat-70.0%
    Jun 25
    		$-0.57$0.38-250.00%Miss+36.0%
    Mar 25
    		$-0.65$-0.69+5.80%Beat+22.6%
    Dec 24
    		$-0.82$-0.59-38.64%Miss-9.1%
    Sep 24
    		$0.90$0.60+50.00%Beat+273.1%
    Jun 24
    		$-0.89$-0.59-50.85%Miss-27.1%
    Mar 24
    		$-0.84$-0.64-31.25%Miss-37.7%
    Dec 23
    		$-0.75$-0.15-400.00%Miss-457.1%
    Sep 23
    		$-0.52$-0.35-48.57%Miss-30.0%
    Jun 23
    		$-0.70$-0.50-40.00%Miss-4.5%
    Mar 23
    		$-0.61$0.35-274.29%Miss+43.5%
    Dec 22
    		$0.21$0.10+110.00%Beat+122.1%
    Sep 22
    		$-0.40$-0.36-11.11%Miss+53.5%
    Jun 22
    		$-0.67$-0.97+30.93%Beat-1.5%
    Mar 22
    		$-1.08$-0.85-27.06%Miss-20.0%
    Dec 21
    		$-0.95$-0.81-17.28%Miss-2275.0%
    Sep 21
    		$-0.86$-0.71-21.13%Miss-30.3%
    Jun 21
    		$-0.66$-0.41-60.98%Miss+29.8%
    Mar 21
    		$-0.90$-0.63-42.86%Miss+1.1%
    Dec 20
    		$-0.04N/A+93.33%Beat+93.5%
    Sep 20
    		$-0.66$-1.02+35.29%Beat+27.5%
    Jun 20
    		$-0.94$-1.00+6.00%Beat+10.5%
    Mar 20
    		$-0.91$-1.02+10.78%Beat+8.1%
    Dec 19
    		$-0.62$-1.16+46.55%Beat+41.5%
    Sep 19
    		$-0.91$-1.11+18.02%Beat-12.3%
    Jun 19
    		$-1.05$-1.07+1.87%Beat-1.9%
    Mar 19
    		$-0.99$-0.87-13.79%Miss+26.1%
    Dec 18
    		$-1.06$-1.02-3.92%Miss-135.8%
    Sep 18
    		$-0.81$-1.30+37.69%Beat+36.7%
    Jun 18
    		$-1.03$-1.21+14.88%Beat+9.6%
    Mar 18
    		$-1.34$-1.10-21.82%Miss-24.1%
    Dec 17
    		$2.96$2.21+33.94%Beat+396.0%
    Sep 17
    		$-1.28$-1.04-23.08%Miss-32.0%
    Jun 17
    		$-1.14$-1.00-14.00%Miss-
    Mar 17
    		$-1.08$-0.91-18.68%Miss-
    Dec 16
    		$-1.00$-0.89-12.36%Miss-
    Sep 16
    		$-0.97$-0.83-16.87%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.99EV/EBITDA-1.54x
    Price/FCF-3.87xFCF Yield-25.83%
    Profitability
    Profit Margin-8.33%Operating Margin-42.20%
    ROE-225.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-2.24x
    Current Ratio2.96xQuick Ratio2.96x
    Trading Statistics
    Beta1.22Avg Volume509.87K
    52-Week High$5.0852-Week Low$1.29

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.09
    SMA 20$4.05
    SMA 50$4.23
    SMA 200$2.97
    EMA 10$4.07
    EMA 20$4.07
    EMA 50$4.07
    EMA 200$3.28

    MACD

    Line: -0.01Signal: -0.02Hist: 0.01

    ADX

    ADX: 13.6+DI: 14.8-DI: 19.5

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down16.0
    PSAR$4.28

    Bollinger Bands

    Upper Band$4.23
    Lower Band$3.88
    %B Position847%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    46.8

    Momentum Oscillators

    Stoch %K53.7
    Stoch %D56.7
    Williams %R-60.9
    ROC (10d)-1.7%
    Momentum-0.07
    CCI (20d)-45.2
    MFI (14d)52.3

    Volatility Measures

    ATR (14d)$0.22(5.4%)
    StdDev (20d)0.09
    Hist Vol39.1%(Moderate)

    Volume Flow

    VWAP$4.01
    OBV54.1M
    AD Line-42.3M
    CMF (20d)-0.004

    Volume Metrics

    Avg Vol (20d)510.5K
    Vol Ratio1.1x
    VWMA (20d)$4.06

    Pivot Points

    R3$4.37
    R2$4.26
    R1$4.20
    Pivot Point$4.08
    S1$4.02
    S2$3.91
    S3$3.85

    Advanced Oscillators

    TSI-1.30
    Ultimate Osc49.1
    KST-12.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.83M$20.77M$41.23M$72.84M$6.87M$13.19M$19.35M$110.71M$10.80M$9.10M$10.72M$10.40M
    Cost of Revenue$0$0$11.82M$0$0$0$233,000$168,000$176,000$270,000$163,000$85,000
    Gross Profit$32.83M$20.77M$41.23M$72.84M$6.87M$13.19M$19.12M$110.54M$10.62M$8.83M$10.56M$10.31M
    Operating Expenses$46.68M$54.21M$53.32M$54.20M$50.09M$55.82M$71.96M$56.35M$68.80M$62.58M$59.91M$45.81M
    R&D$38.78M$34.97M$33.97M$32.71M$40.79M$39.70M$38.89M$40.54M$51.73M$46.03M$47.35M$30.13M
    SG&A$7.90M$9.71M$9.23M$9.90M$9.30M$10.72M$27.81M$14.10M$14.42M$14.71M$12.56M$12.41M
    Operating Income$-13,852,000$-33,439,000$-12,095,000$18.64M$-43,224,000$-42,624,000$-52,838,000$54.19M$-58,181,000$-53,750,000$-49,354,000$-35,502,000
    Interest Income$-52,762,000$0$0$0$0$0$0$0$0$0$0$50.00M
    Interest Expense$4.40M$4.89M$4.27M$3.34M$802,000$91,000$-24,000$0$6,000$1.13M$0$0
    Income Before Tax$-69,642,000$-38,328,000$-13,253,000$16.82M$-42,612,000$-42,715,000$-11,784,000$56.31M$-55,664,000$-54,883,000$-39,668,000$14.50M
    Income Tax Expense$0$0$0$0$105,000$0$0$0$0$0$0$0
    Net Income$19.52M$-36,774,000$-14,155,000$16.82M$-36,251,000$-41,036,000$-15,421,000$56.31M$-55,664,000$-52,190,000$-46,072,000$17.55M
    EBITDA$-12,221,000$-32,489,000$-11,034,000$21.44M$-40,214,000$-41,035,000$-50,970,000$57.77M$-54,786,000$-53,224,000$-49,182,000$-35,424,000
    EBIT$-12,484,000$-33,439,000$-12,095,000$20.16M$-41,810,000$-42,624,000$-52,838,000$56.31M$-55,658,000$-53,750,000$-49,354,000$-35,502,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MGNX

    News

    Macrogenics senior VP sells $129,085 in shares By Investing.com

    Jeffrey Stuart Peters, Senior VP at MacroGenics Inc., sold 31,105 shares of company common stock totaling $129,085 on August 19, 2026, as part of a Rule 10b5-1 trading plan. Following this transaction, Mr. Peters directly owns no shares of MacroGenics common stock. This insider sale follows a 172% surge in MacroGenics shares over the past year, with the stock currently trading at $4.07, and comes amidst the company's recent strategic developments and financial activities.

    Investing.com Nigeria•8/21/26•
    Somewhat-Bearish

    Macrogenics senior VP sells $129,085 in shares By Investing.com

    Jeffrey Stuart Peters, Senior VP at MacroGenics Inc., sold 31,105 shares of company common stock totaling $129,085 on August 19, 2026. This sale was part of a Rule 10b5-1 trading plan and follows a 172% surge in MacroGenics shares over the past year. The company has also recently announced significant developments including the sale of its manufacturing operations, a milestone payment from Sanofi, and an option exercise by Gilead Sciences.

    Investing.com South Africa•8/20/26•
    Somewhat-Bearish

    MacroGenics (MGNX) counsel sells 31K shares, now holds none

    Jeffrey Stuart Peters, Senior VP, GC, and Secretary of MacroGenics (MGNX), sold 31,105 shares of common stock on August 19, 2026, under a Rule 10b5-1 trading plan. The shares were sold at an average price of $4.15, totaling $129K. Following this transaction, Peters no longer holds any MacroGenics common stock directly.

    Stock Titan•8/20/26•
    Bearish

    Macrogenics senior VP sells $129,085 in shares

    Jeffrey Stuart Peters, Senior VP at MacroGenics Inc., sold 31,105 shares of company common stock for $129,085 on August 19, 2026, as part of a Rule 10b5-1 trading plan. This insider sale follows a 172% surge in MacroGenics shares over the past year. The company recently completed a $122.5 million sale of manufacturing operations to Bora Pharmaceuticals and expects a $24.5 million milestone payment from Sanofi for TZIELD's FDA approval, while also seeing Gilead Sciences exercise an option on a preclinical program.

    Investing.com•8/20/26•
    Neutral

    MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144

    Jeffrey Peters, an officer at MacroGenics (NASDAQ: MGNX), has filed a Form 144 indicating his intent to sell common shares acquired through stock plan activity in 2025 and 2026. These shares may be sold through Merrill Lynch on NASDAQ once Rule 144 conditions are met. The filing details multiple blocks of stock and confirms the proposed sales rather than completed transactions.

    Stock Titan•8/19/26•
    Neutral

    Frequently Asked Questions About MGNX

    Does MGNX pay dividends?
    MacroGenics Inc (MGNX) does not currently pay a regular dividend.
    What is MGNX's market cap?
    MacroGenics Inc (MGNX) has a market capitalization of $263.08M with a current stock price of $3.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In